EGFR mutations are associated with response to depatux-m in combination with temozolomide and result in a receptor that is hypersensitive to ligand
Youri Hoogstrate(Erasmus MC), Pim J. French(Erasmus MC Cancer Institute), Annemiek Walenkamp(University Medical Center Groningen), Maurice de Wit(Erasmus MC Cancer Institute), Martin E. van Royen(Erasmus MC), Martin J. van den Bent(Erasmus MC Cancer Institute), Michael Weller(University Hospital of Zurich), Iris de Heer(Erasmus MC Cancer Institute), Jim Looman(AbbVie (United States)), Earle Bain(AbbVie (United States)), Peter Ansell(AbbVie (United States)), Thierry Gorlia(European Organisation for Research and Treatment of Cancer), Jean‐Sébastien Frenel(Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes Angers), Marica Eoli(Fondazione IRCCS Istituto Neurologico Carlo Besta), Enrico Franceschi(Istituto delle Scienze Neurologiche di Bologna), Marie Morfouace(European Organisation for Research and Treatment of Cancer), Johan M. Kros(Erasmus MC), Juan Manuel Sepúlveda-Sánchez(Hospital Universitario 12 De Octubre), Wies Vallentgoed(Erasmus MC Cancer Institute), Vassilis Golfinopoulos(Champalimaud Foundation), Paul M. Clément(Universitair Ziekenhuis Leuven)
Cited by 17
Related Papers
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
|New England Journal of Medicine|2016|2k
EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood
|Nature Reviews Clinical Oncology|2020|1.9k
Medulloblastoma Comprises Four Distinct Molecular Variants
|Journal of Clinical Oncology|2010|1.4k
Intertumoral Heterogeneity within Medulloblastoma Subgroups
|Cancer Cell|2017|1.3k